Consolidated Financial Statements	3 Months Ended
Aug. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidated Financial Statements	CONSOLIDATED FINANCIAL STATEMENTS The Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three months ended August 31, 2026 and 2025, the Consolidated Balance Sheet as of August 31, 2026, the Consolidated Statements of Cash Flows for the three months ended August 31, 2026 and 2025, and the Consolidated Statements of Stockholders’ Equity for the three months ended August 31, 2026 and 2025 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2026 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2026 (and for all periods presented) have been made. The unaudited interim consolidated financial statements for the three months ended August 31, 2026 and 2025 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries (collectively, the "Company", "we", "our" or "us"). All intercompany balances and transactions have been eliminated.

Consolidated Financial Statements

3 Months Ended

Aug. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

CONSOLIDATED FINANCIAL STATEMENTS

The Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three months ended August 31, 2026 and 2025, the Consolidated Balance Sheet as of August 31, 2026, the Consolidated Statements of Cash Flows for the three months ended August 31, 2026 and 2025, and the Consolidated Statements of Stockholders’ Equity for the three months ended August 31, 2026 and 2025 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2026 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2026 (and for all periods presented) have been made.

The unaudited interim consolidated financial statements for the three months ended August 31, 2026 and 2025 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries (collectively, the "Company", "we", "our" or "us"). All intercompany balances and transactions have been eliminated.